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Abstract
Background and aim Long-term changes in gastrointestinal function impacting quality of life after treatment for cancer are
common. Peer reviewed guidance to investigate and manage GI dysfunction following cancer treatment has been published. This
study reviewed gastrointestinal symptoms of women previously treated for gynaecological cancer and considered whether
suggested algorithms could be amended to optimise management for this cohort.
Methods Demographic and clinical data recorded for patients attending a specialist consequences of cancer treatment gastroen-
terology service prospectively are reported using median and range. The Wilcoxon signed rank test analysed changes in
symptoms between initial assessment to discharge from the service.
Results Between April 2013 and March 2016, 220 women, with a median age of 57 years (range 24–83 years), treated for
gynaecological cancer (cervical (50%)), endometrial (28%), ovarian (15%), vaginal or vulval (7%) attended. Twelve gastroin-
testinal symptoms were statistically significantly reduced by time of discharge from the specialist gastroenterology clinic
including bowel frequency ≥ 4/day (88%), type 6 or 7 stool consistency (36%), urgency (31%) and incontinence (21%).
General quality of life improved from a median score of 4 at first assessment to a median of 6 at discharge (p < 0.001). A median
of four (range, 1–9) diagnoses were made.
Conclusion Women with gastrointestinal symptoms after cancer treatment benefit from a systematic management approach.
After excluding disease recurrence, a proposed investigational algorithm and the oncology team includes FBC, U&Es, LFTs,
thyroid function test, vitamin B12, vitamin D, a hydrogen methane breath test and a SeHCAT scan. If rectal bleeding is present,
iron studies, flexible sigmoidoscopy or colonoscopy should be performed. Patients with normal investigations or symptoms not
responding to treatment require gastroenterology input.
Keywords Cancer . Gynaecological malignancy . Chemotherapy . Radiotherapy . Gastrointestinal . Side effects . Toxicity .
Quality of life . Bile acid malabsorption . Small intestinal bacterial overgrowth . Endoscopy . Diarrhoea . Abdominal pain .
Bloating . Incontinence . Urgency . Late effects . Consequences of treatment
Background
Cancer survival has doubled in the last 40 years. Half of peo-
ple diagnosed with cancer in England and Wales survive for
10 years or more [1]. Advances in multi-modal treatments
offer better chances of survival but impact on the body in
multiple ways, not only during treatment but long-term. The
long-term impact of cancer treatment was the focus of the
National Survivorship Initiative and has been adopted in the
NHS England cancer plan [2, 3].
The Royal Marsden Gastrointestinal and Nutrition Team
(GIANT) service, a clinic established specifically to care for
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patients experiencing ongoing gastrointestinal symptoms after
cancer treatment, is multidisciplinary with input from a con-
sultant gastroenterologist, specialist nurses and dietitians.
The team developed a systematic, checklist-based ap-
proach to assess and investigate these long-term gastroin-
testinal symptoms, tested in the ORBIT study [4]. This
showed that patient outcomes when managed by a spe-
cialist nurse were not inferior to those managed by a con-
sultant gastroenterologist. Subsequent evaluation of this
clinical service suggested that the cost of managing gas-
trointestinal consequences of cancer treatment across tu-
mour groups averages £1563 per patient [5].
The algorithm used to manage patients’ abnormal symp-
toms was developed through 10 peer-reviewed versions [6]
without regard to the primary cancer site treated. Since differ-
ent treatment pathways are used for each type of cancer—
including type of surgery, chemotherapy regimens, radiother-
apy volumes and doses—the predominant causes for long-
term gastrointestinal symptoms may vary. This may allow
for a tailored algorithm in some patient groups.
Annually, 21,000 UK women are newly diagnosed with a
gynaecological malignancy [7]. Following treatment for
gynaecological cancer, data are inadequate to assess how
many women experience permanent changes to gastrointesti-
nal function which impact on quality of life, activity levels or
return to work; however, several studies have highlighted this
as a serious concern [8–11].
The aims of this study were to evaluate the symptoms of
women previously treated for gynaecological cancer, assessed
in a specialist gastroenterology clinic and to review whether
the established algorithm could be amended to optimise man-
agement in this cohort by the gynaecology team. The study
hypothesis was that there would be an improvement in symp-
tom severity at discharge from the gastroenterology clinic
compared with baseline.
Methods
This was an observational study with data collected prospec-
tively on all users of the GIANT service. Following institu-
tional review board approval for service evaluation (SE36),
demographic and clinical data were collected on a clinical
research form and entered onto database. Data included all
requested investigations, resulting gastrointestinal diagnoses
and treatments as dictated by the algorithm for patients who
completed their episode of care from the clinic.
At each clinic visit, patients self-reported the presence and
severity of their symptoms using a modified Gastrointestinal
Symptom Rating Scale (GSRS). Symptom severity is
categorised as ‘causes major changes in your life’, ‘frequently
affecting your life’, ‘occasional’ or ‘never’. The first two cat-
egories indicate severe and moderate symptoms. The GSRS
has been validated for use in a wide variety of gastrointestinal
disorders [12–15]. Patients indicated the frequency of bowel
movements and stool consistency using a Bristol stool chart
with 1 = hard stool and 7 = liquid stool [16]. In addition, they
scored their perceived quality of life (QoL) on a visual ana-
logue scale (VAS) with 0 indicating the worst possible QoL
and 10 equating the best possible QoL and the impact of their
gastrointestinal symptoms onQoLwith 0 indicating no impact
and 10 the worst impact possible.
A holistic needs assessment (HNA) was also offered to all
patients at first assessment. The HNA comprises a question-
naire covering areas which may concern anyone living with
and beyond cancer [2]. Practical, emotional and spiritual fam-
ily issues can be identified to discuss with a qualified health
care professional or highlighted as a concern without discus-
sion, alongside physical concerns. As part of the assessment,
the distress thermometer—a screening tool for assessing psy-
chological distress in people affected by cancer—is a require-
ment of the National Institute of Clinical Excellence guide-
lines for supportive and palliative care [17]. Patients scored on
a scale from 0 (‘I am not distressed’) to 10 (‘I am extremely
distressed’). A score of more than 7 justifies a psychological
support service referral in a tertiary cancer centre [18].
TheWilcoxon signed rank test was used to analyse changes
in symptom burden between initial assessment and the point
of discharge from the service. This statistical analysis test
allows for comparison of ordinal data (symptom severity) be-
tween 2 related groups.
Results
Between April 2013 and March 2016, there were 1158
new patients and 2686 follow-up appointments in the
GIANT clinic. Two hundred thirty-five women (21%)
had received treatment for gynaecological malignancy.
Fifteen women who declined investigations and further
management were excluded, leaving 220 for analysis.
Referral to the clinic came from within the organisation
(n = 94; 43%), other hospitals (n = 77; 35%), general
practitioners (n = 48; 22%) and self-referral (n = 1; < 1%).
The primary cancer site was cervix (n = 109; 50%), endo-
metrium (n = 62; 28%), ovary (n = 33; 15%) and vagina or
vulva (n = 16; 7%). The median age was 57 years (range, 24–
83). Several women received multi-modal therapies for their
malignancy (Table 1). Nearly 70% (n = 151) received radio-
therapy (including brachytherapy), 54% (n = 118) had surgery
and 45% (n = 98) chemotherapy. Seventeen percent (n = 37)
received all three therapies. Treatment characteristics per tu-
mour group are presented in Table 1. The median time be-
tween cancer diagnosis and referral was 4 years and 10months
(range, 6 months–47.5 years). Ten percent of women had been
seen previously and were re-referred. In patients seen for the
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first time, the median number of consultations was 4 (range,
1–17) with 38% requiring more than four. Those who were re-
referred had a median of 4 consultations (range, 1–7) with
30% needing more than four.
The most prevalent gastrointestinal symptoms at assess-
ment rated as severe included increased frequency of
defaecation (88%), diarrhoea (36%), urgency (31%) and in-
continence (21%). In addition, many women also reported
fatigue (87%), urinary problems (53%) and sexual concerns
(38%) (Fig. 1).
A median of 8 (range, 1–14) investigations were requested
for this cohort using our algorithm version 10 [6]. These in-
cluded blood screen (n = 213; 97%), gastroscopy (n = 178;
80%) with duodenal aspirate (n = 168; 76%), glucose hydro-
gen methane breath test (n = 177; 80%), SeHCAT scan (n =
161; 73%), stool sample for faecal elastase (n = 152; 69%),
flexible sigmoidoscopy (n = 114; 52%), colonoscopy (n = 56;
25%) and abdominal X-ray (n = 35; 16%).
These investigations revealed a median of four abnor-
mal findings (range, 1–9) with 68% of women (n = 150)
having more than three. Blood screens showed that vita-
min D deficiency is common in this group (60%). The
vitamin B12 test was below the normal range for 30% of
this cohort (n = 65). Thyroid function tests indicated ab-
normal values for 5% (n = 11) (Table 2).
Following the algorithm, in the presence of upper GI
symptoms, a gastroscopy with duodenal aspirate was of-
ten ordered to test for small intestinal bacterial
overgrowth (SIBO) in addition to upper gastrointestinal
pathology. In this cohort, more than 75% (n = 168) of
women had a duodenal aspirate. Of those, 60% (n =
101) did not report any growth. Of the 40% (n = 67)
that did, half of the cases (n = 35) had sensitivities re-
ported resulting in specific antibiotic treatment which in
15% (n = 5) differed from the recommendation of the
algorithm. One hundred seventy-seven women had a
glucose hydrogen methane breath test which was posi-
tive for both hydrogen and methane in 24% (n = 43), for
methane alone in 12% (n = 22) and for hydrogen alone
in 8% (n = 14). Nearly a third of women (n = 33) with
persistent symptoms required multiple treatments with
antibiotics (range, 2–9) and two women required long-
term, rotating antibiotics.
Bile acid malabsorption was a common diagnosis in this
group of women (n = 104; 47%); 73% (n = 161) had a
SeHCAT scan which was positive in 65% (n = 104). The al-
gorithm suggests that a SeHCAT should be requested for any-
one reporting type 6 or 7 stool consistency, urgency or steat-
orrhoea [6]. For those women who reported urgency without
diarrhoea, 60% (n = 54) had a positive SeHCAT scan.
Faecal loading complicated by overflow diarrhoea was
diagnosed following an abdominal X-ray in 8% of the
cohort (n = 18).
A stool sample for faecal elastase, sent in 69% (n =
152), confirmed pancreatic insufficiency in 7% (n = 16)
requiring treatment with enzyme replacement and
Table 1 Cancer treatment regimens per cancer diagnosis group (n = 220)
Cervical cancer, n (%) Endometrial cancer, n (%) Ovarian cancer, n (%) Vaginal/vulval
cancer, n (%)
Total, n (%)
Cancer treatment
Chemotherapy alone 11 1 8 2 22 (10%)
Radiotherapy alone 36 13 1 2 52 (24%)
Surgery alone 10 16 11 2 39 (18%)
CXT+RT (no surgery) 24 1 0 3 28 (13%)
CXT+ surgery (no RT) 0 0 8 3 11 (5%)
RT + surgery (no CXT) 12 18 0 1 31 (14%)
CXT+RT + surgery 16 13 5 3 37 (17%)
Total 109 (50%) 62 (28%) 33 (15%) 16 (7%) 220 (100%)
Additional cancer treatment information per cancer diagnosis group (n = 220)
EBRTw/o brachytherapy 37 29 5 4 71 (32%)
Brachytherapy w/o EBRT 3 3 0 1 7 (3%)
EBRT + brachytherapy 48 13 4 4 69 (31%)
RT total 88 (40%) 45 (20%) 9 (4%) 9 (4%) 151 (69%)
Chemotherapy total 51 (23%) 15 (7%) 21 (10) 11 (5%) 98 (45%)
Surgery total 38 (17%) 47 (21%) 24 (11%) 9 (4%) 118 (54%)
Hormone replacement therapy 1 4 4 0 9 (4%)
Other treatment 0 0 0 0 0
Colostomy 1 0 0 1 2 (1%)
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sometimes specialist dietetic advice. A coeliac screen was
requested in 84% of the women (n = 185) but did not
identify any women with the condition.
The holistic needs assessment was completed by 71% (n =
157) (Fig. 2). The main concerns for women after treatment
for gynaecological cancer were fatigue (70%), worry, fear and
anxiety (62%), sleeping problems (58%) and pain (57%).
Women scored a median of 5 (range, 0–10) on the distress
thermometer and 35% (n = 59) scored 7 or more.
Twelve gastrointestinal symptoms were statistically
significantly reduced by time of discharge from the spe-
cialist gastroenterology clinic (Table 3) (p < 0.05). The
general quality of life score improved from a median of
4 at first assessment to a median of 6 at discharge (p <
0.001). The impact of residual or recurrent gastrointestinal
symptoms on QoL did not improve with a median of 7 out
of a maximum score of 10 (p > 0.05).
Discussion
This prospective cohort study shows that a specialist gastro-
enterology service can improve the outcomes for women liv-
ing with and beyond cancer after treatment for gynaecological
malignancy by reducing gastrointestinal symptom burden and
improving quality of life.
The findings of this study are consistent with other studies
[19] which show that the main concerns for women on holistic
needs assessment are largely unchanged from their concerns at
the end of treatment and in 1 in 3 justify a psychological
Table 2 Prevalence of new gastrointestinal or nutritional diagnoses
(n = 220)
Diagnosis Prevalence, n (%)
Vitamin D deficiency 133 (60%)
Small intestinal bacterial overgrowth 118 (54%)
Bile acid malabsorption 104 (47%)
Gastritis 68 (31%)
Vitamin B12 deficiency 65 (30%)
Weak pelvic floor musculature on rectal exam 36 (21%)
Telangiectasia on the rectal wall 33 (15%)
Trace element deficiency 31 (14%)
New GI polyp 24 (11%)
Hiatus hernia 22 (10%)
Faecal loading (confirmed on abdominal X-ray) 18 (8%)
Dietary fibre excess on fibre quiz 16 (7%)
Oesophagitis 16 (7%)
Iron deficiency 16 (7%)
Pancreatic insufficiency 16 (7%)
Duodenitis 13 (6%)
Thyroid problems 11 (5%)
Diverticular disease 9 (4%)
Gastro-oesophageal reflux disease 8 (4%)
Haemorrhoids 7 (3%)
Inflammatory bowel disease 4 (2%)
Rectal ulcer 4 (2%)
New GI cancer 5 (2%)
Anal fissure/anal sphincter defect 3 (1%)
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Fig. 1 Paired symptom scores (n = 220) at baseline and discharge; left bar, baseline assessment; right bar, discharge assessment (NS, not significant,
*p < 0.05)
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support service referral because of worry, fear and anxiety,
fatigue and sleeping problems.
The relatively high prevalence of symptoms still pres-
ent at discharge may partly be related to the fact that
whilst specific treatments help improve symptoms, as
yet there are no proven treatments to tackle the underlying
pathological changes which cause pelvic radiation disease
[20]. Despite this, there remains scope for further im-
provement. Support delivered by a specialist multidisci-
plinary team may have a beneficial psychological effect in
itself. Furthermore, the importance to provide person-
centred care and use patient recorded outcome measures
(PROMS) is highlighted by the suggestion that even
though general QoL improves from baseline, the impact
of residual or recurring gastrointestinal symptoms on QoL
remains the same at discharge. This may be due to height-
ened awareness of the causes contributing to these symp-
toms and need for ongoing, long-term management strat-
egies including demanding lifestyle and dietary changes.
Whilst the reduction in severity reached statistical sig-
nificance in 12 out of 20 gastrointestinal symptoms, the
average time from diagnosis of cancer to referral to a
specialist gastroenterology service was nearly 5 years.
There is a need for earlier identification of patients requir-
ing intervention. One way to do this is by developing
assessment measures such as the ALERT-B questionnaire
validated for use in oncology follow-up clinics in patients
with prostate cancer who may benefit from further assess-
ment [21]. After excluding disease progression, the next
logical step would be for the oncology team to initiate
first-line investigations to identify treatable symptoms.
To this end, this study suggests an investigational algo-
rithm tailored to symptomatic gynaecological oncology
patients which any team should not find challenging. If
symptoms remain unresolved or these tests are negative, a
referral can be made to specialist gastroenterology ser-
vices (Table 4).
Within this cohort, several tumour sub-groups were
represented with different treatment regimens. Whilst
nearly 70% received radiotherapy to the pelvic area, near-
ly 50% also received other treatments, making it difficult
to establish which treatment modality contributes to gas-
trointestinal symptom burden. The heterogeneity of the
patients included in the study regarding tumour and treat-
ment types could limit the applicability of the algorithm to
each different cancer type, treatment and stage. Further
testing is needed to provide evidence of its use in clinical
practice and its merit in reducing symptom burden for
these patients.
In this study, two-thirds of women were deficient in vita-
min D. Clinical evidence supports that adequate vitamin D
levels or supplementation in those with low levels reduces
the risk of developing gynaecological malignancies although
the molecular pathways remain poorly understood [22].
Vitamin D is essential to aide the absorption of calcium and
maintain bone health [23] and after pelvic radiotherapy pa-
tients are at increased risk of bone fractures. Whilst in the
general population supplementation of vitamin D does not
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Fig. 2 Concerns highlighted by women treated for gynaecological malignancy on the holistic needs assessment (n = 157)
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improve bone health [24], this may be different in a cancer
population and people with bile acid malabsorption.
Vitamin B12 deficiency is a potent cause for tiredness and is
linked to memory problems, anaemia and breathlessness.
Levels are often low in those with bile acid malabsorption
and SIBO [25–27]. Up to 23% of women treated for
gynaecological cancer were previously reported to have de-
creased vitamin B12 levels [28] and in this cohort, it was de-
tected in 30%.
Interpretation of all currently available investigations to
diagnose SIBO is problematic [29] and it is difficult to ascer-
tain how effective treatment for SIBO is without systematic
re-testing. A breath test should remain a first-line test in this
patient cohort. In view of antibiotic stewardship [30], a duo-
denal aspirate may be helpful in people with recurrent SIBO
or persistent symptoms.
Bile acid diarrhoea has an estimated prevalence in the
general population of 1% and is frequently misdiagnosed
as IBS [31, 32]. Bile acid malabsorption was diagnosed
in 47% in our cohort. Some of these may have had
primary bile acid diarrhoea and unrecognized pre-treat-
ment, which exacerbated during treatment but for many,
new onset symptoms were likely secondary to the effect
of chemo-radiotherapy on the absorptive capacity for bile
of the terminal ileum. Our finding is in keeping with
other studies. Bile acid malabsorption is often thought
as causing chronic watery stool. We have previously
shown that a wide spectrum of symptoms improves when
bile acid malabsorption is adequately treated [33]. It is
therefore particularly interesting that 40% of patients in
whom we made this diagnosis only had urgency and did
not report loose stool. In some, opioids or anti-diarrhoeal
medication may have masked their diarrhoea; this high-
lights that urgency in this patient group may be a marker
for bile acid malabsorption.
Constipation is common in up to 60% of cancer pa-
tients and can be due to several causes following treat-
ment: small intestinal bacterial overgrowth, reduced die-
tary fibre intake, medication, anorectal pain, anal fissure
and co-morbidities such as diabetes [34]. Although bowel
obstruction occurs more often in women treated for ovar-
ian cancer, it is important to differentiate this from severe
faecal loading through imaging [35]. In this cohort, ab-
dominal X-ray had a 50% yield for identifying faecal
loading which was thought to predispose to abdominal
pain or overflow diarrhoea.
In this group, a stool sample for faecal elastase, which
costs about £39, has a 7% yield for diagnosing pancreatic
insufficiency. Thyroid function problems were detected in
only 5% of patients but are routinely included in our
blood screen which was done in 97% of the cohort. A
coeliac screen is also routinely included, especially as
people often cut gluten out of their diet. The cost of a
Table 3 Symptoms which improved at a statistically significant level
(p < 0.05), n = 220
Symptoms Baseline (n = 220) Discharge (n = 220) p value
n (%) n (%)
Perianal pain
No problem 96 (44) 125 (57)
Mild 63 (29) 63 (29) < 0.001
Moderate 40 (18) 25 (11)
Severe 21 (10) 7 (3)
Bloating
No problem 50 (23) 62 (28)
Mild 69 (31) 92 (42) < 0.001
Moderate 81 (37) 52 (24)
Severe 20 (9) 14 (6)
Flatulence
No problem 31 (14) 37 (17)
Mild 78 (35) 109(50) < 0.001
Moderate 79 (36) 65 (30)
Severe 32 (15) 9 (4)
Borborygmi
No problem 34 (15) 50 (23)
Mild 95 (43) 112 (51) < 0.001
Moderate 68 (31) 50 (23)
Severe 23 (10) 8 (4)
Vomiting
No problem 121 (55) 136 (62)
Mild 62 (28) 69 (31) 0.002
Moderate 27 (12) 11 (5)
Severe 10 (5) 4(2)
Urgency
No problem 27 (12) 24 (11)
Mild 47 (21) 81 (37) < 0.001
Moderate 77 (35) 78 (35)
Severe 69 (31) 37 (17)
Tenesmus
No problem 35 (16) 37 (17) 0.003
Mild 68 (31) 94 (43)
Moderate 75 (34) 65 (30)
Severe 42 (19) 24 (10)
Faecal incontinence
No problem 50 (23) 60 (28)
Mild 59 (27) 85 (39) < 0.001
Moderate 58 (26) 45 (20)
Severe 53 (24) 30 (14)
Steatorrhoea
No problem 119 (54) 127 (58)
Mild 54 (25) 66 (30) 0.045
Moderate 40 (18) 22 (10)
Severe 7 (3) 5 (2)
Nocturnal defaecation
No problem 72 (33) 83 (38)
Mild 78 (35) 94 (43) < 0.001
Moderate 51 (23) 34 (15)
Severe 19 (9) 9 (4)
Bowel frequency > 4x/day
No 26 (12) 39 (18) 0.009
Yes 194 (88) 181 (82)
Diarrhoea (type 6 or 7)
No 142 (65) 165 (75) 0.013
Yes 78 (35) 55 (25)
Fatigue
No problem 28 (13) 26 (12)
Mild 64 (29) 93 (42) 0.001
Moderate 74 (34) 67 (30)
Severe 54 (26) 34 (15)
Sexual concerns
No problem 137 (62) 147 (67)
Mild 28 (13) 27 (12) 0.004
Moderate 27 (12) 22 (10)
Severe 28 (13) 24 (11)
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coeliac screen is about 25–£40 with on-costs (personal
communication). As we did not identify any new onset
of coeliac disease in this cohort, and the low yield of
faecal elastase and coeliac screening, it may be reasonable
not to include them in the oncology clinic; however, this
may delay diagnosis, affect clinic capacity and potentially
increase costs as patients may require additional appoint-
ments before treatment has been optimised.
The most common and severe symptoms in this cohort
were urgency and type 6 or 7 stool consistency. A new tiered
approach to investigation (Table 2) in this cohort may facili-
tate the management of symptoms as it can be difficult to
know which intervention has resulted in improvement or
failed to have an impact.
In this prospective cohort, we were unable to correlate gas-
trointestinal symptoms to disease stage, treatment modalities,
radiotherapy volumes or doses but this is important to include
in further studies. Differences in disease stage could have
influenced symptom incidence, severity and outcome. Pelvic
radiotherapy is used to treat gynaecological malignancies in
30% of women. Moderate to severe long-term gastrointestinal
symptoms are reported by clinicians in 5–15% of patients
treated [36] and up to 50% when PROMs are used [37, 38].
Extrapolat ing the number of patients treated for
gynaecological malignancies with pelvic radiotherapy, this
would mean up to 3225 women need access to this kind of
service in the UK where 21,500 gynaecological cancer diag-
noses are made yearly [7].
Conclusion
Significant improvement in gastrointestinal symptoms for
women with long-term bowel problems following treatment
for gynaecological cancer can be achieved. The most common
functional deficits are bile acid malabsorption, small intestinal
bacterial overgrowth and vitamin D deficiency. The proposed
investigational algorithm tailored to this cohort will need to be
tested further in clinical practice to ascertain its clinical value.
There is a need for earlier intervention and further research for
predicting and treating bowel toxicity which correlates GI
symptom burden with radiotherapy volumes and doses.
Table 4 Investigation algorithm tailored for women treated for gynaecological cancer with ongoing GI problems
Investigational algorithm tailored for gynaecological cancer Original investigational algorithm (Frontline Gastroenterology, 2015)
First-line investigations (oncology clinic) First-line investigations
Blood screen:
FBC, U&Es, LFTs
Vitamin D
Vitamin B12
Blood screen:
FBC, U&Es, LFTs, CRP, ESR
Vitamin D
Vitamin B12
Iron studiesGlucose hydrogen methane breath
SeHCAT scan Thyroid function
Coeliac screen
Serum magnesium
If rectal bleeding is present: iron studies
Flexible sigmoidoscopy or colonoscopy (avoid biopsies of irradiated tissue)
If no rectal bleeding but anaemic: iron studies
Flexible sigmoidoscopy or colonoscopy (avoid biopsies of irradiated tissue)
Stool sample for microscopy, culture and Clostridium difficile
Stool sample for faecal elastase
Second-line investigations (gastroenterology team) Glucose hydrogen methane breath test
Gastroscopy with duodenal aspirate
Stool sample for faecal elastase Carbohydrate challenge
Coeliac screen SeHCAT scan
Thyroid function screen Flexible sigmoidoscopy/colonoscopy (avoid biopsies of irradiated
tissue)
Abdominal X-ray Second-line investigations
Third-line investigations (gastroenterology team) Colonoscopy with biopsies
Carbohydrate challenge Third-line investigations
Gut hormone blood test, urinary 5-HIAA Gut hormone challenge
Colonoscopy with biopsies Urinary 5-HIAA
CT chest abdomen and pelvis/CT colonography to exclude structural GI pa-
thology
CT chest abdomen and pelvis
Support Care Cancer
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